MX2009013472A - Polipeptido ace2. - Google Patents

Polipeptido ace2.

Info

Publication number
MX2009013472A
MX2009013472A MX2009013472A MX2009013472A MX2009013472A MX 2009013472 A MX2009013472 A MX 2009013472A MX 2009013472 A MX2009013472 A MX 2009013472A MX 2009013472 A MX2009013472 A MX 2009013472A MX 2009013472 A MX2009013472 A MX 2009013472A
Authority
MX
Mexico
Prior art keywords
ace2 polypeptide
dimer
present
polypeptide
ace2
Prior art date
Application number
MX2009013472A
Other languages
English (en)
Inventor
Manfred Schuster
Hans Loibner
Evelyne Janzek-Hawlat
Bernhard Peball
Stefan Stranner
Bettina Wagner
Robert Weik
Original Assignee
Apeiron Biologics Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP08450052A external-priority patent/EP2108695A1/de
Application filed by Apeiron Biologics Ag filed Critical Apeiron Biologics Ag
Publication of MX2009013472A publication Critical patent/MX2009013472A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/485—Exopeptidases (3.4.11-3.4.19)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/17—Metallocarboxypeptidases (3.4.17)
    • C12Y304/17023—Angiotensin-converting enzyme 2 (3.4.17.23)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se relaciona al polipéptido ACE2 recombinante, donde el polipéptido ACE2 está presente como un dímero. El dímero se forma específicamente de monómeros glicosilados y se usa para producir productos farmacéuticos con una vida media prolongada.
MX2009013472A 2007-06-12 2008-06-12 Polipeptido ace2. MX2009013472A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AT0091307A AT505262A1 (de) 2007-06-12 2007-06-12 Rekombinantes ace2 polypeptid
EP08450052A EP2108695A1 (de) 2008-04-08 2008-04-08 Ace2 Polypeptid
PCT/AT2008/000211 WO2008151347A1 (de) 2007-06-12 2008-06-12 Ace2 polypeptid

Publications (1)

Publication Number Publication Date
MX2009013472A true MX2009013472A (es) 2010-06-25

Family

ID=39720296

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009013472A MX2009013472A (es) 2007-06-12 2008-06-12 Polipeptido ace2.

Country Status (35)

Country Link
US (3) US8586319B2 (es)
EP (3) EP2543724B1 (es)
JP (1) JP5731193B2 (es)
KR (2) KR20160054045A (es)
CN (2) CN101796183A (es)
AT (1) AT505262A1 (es)
AU (1) AU2008261591B2 (es)
BR (1) BRPI0813942B8 (es)
CA (1) CA2692854C (es)
CO (1) CO6270265A2 (es)
CR (1) CR11213A (es)
CY (2) CY1116873T1 (es)
DK (2) DK2543724T3 (es)
DO (1) DOP2009000282A (es)
EA (1) EA027399B1 (es)
EG (1) EG27095A (es)
ES (2) ES2670938T3 (es)
HK (2) HK1255493A1 (es)
HR (2) HRP20151120T1 (es)
HU (2) HUE037877T2 (es)
IL (1) IL202653B (es)
LT (1) LT2543724T (es)
MA (1) MA31472B1 (es)
MX (1) MX2009013472A (es)
MY (1) MY180672A (es)
NO (1) NO2543724T3 (es)
NZ (1) NZ581704A (es)
PL (2) PL2155871T3 (es)
PT (2) PT2155871E (es)
RS (2) RS57292B1 (es)
SI (2) SI2543724T1 (es)
TR (1) TR201808117T4 (es)
UA (1) UA106869C2 (es)
WO (1) WO2008151347A1 (es)
ZA (1) ZA200908751B (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10351615B2 (en) 2006-02-03 2019-07-16 Opko Biologics Ltd. Methods of treatment with long-acting growth hormone
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
US9458444B2 (en) 2006-02-03 2016-10-04 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US8946155B2 (en) 2006-02-03 2015-02-03 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US8048849B2 (en) 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US20150038413A1 (en) 2006-02-03 2015-02-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US10221228B2 (en) 2006-02-03 2019-03-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
AT505262A1 (de) * 2007-06-12 2008-12-15 Apeiron Biolog Forschungs Und Rekombinantes ace2 polypeptid
EP2077119A1 (de) * 2007-12-21 2009-07-08 Apeiron Biologics Forschungs- und Entwicklungsgesellschaft M.B.H. Behandlung von Fibrosen und Lebererkrankungen
AT506632A1 (de) * 2008-04-09 2009-10-15 Apeiron Biolog Forschungs Und Behandlung von tumorerkrankungen
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
US9522945B2 (en) 2012-04-19 2016-12-20 Opko Biologics Ltd. Long-acting oxyntomodulin variants and methods of producing same
SG11201408530YA (en) 2012-08-02 2015-03-30 Hoffmann La Roche Method for producing monomeric and multimeric molecules and uses thereof
BR112015011583B1 (pt) 2012-11-20 2023-03-14 Opko Biologics Ltd Métodos para aumentar o tamanho ou volume hidrodinâmico de hormônio de crescimento humano, método para aumentar o peso molecular aparente de um polipeptídeo e método para aumentar a meia-vida de um polipeptídeo
WO2014108530A1 (en) * 2013-01-14 2014-07-17 Apeiron Biologics Ag Modified ace2 polypeptides
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
US10960058B2 (en) 2015-06-19 2021-03-30 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
TW201808988A (zh) 2016-07-11 2018-03-16 歐科生物製品有限公司 長效型凝血因子及其生產方法
US11518788B2 (en) * 2020-07-10 2022-12-06 Avirus, Inc. Methods and compositions for treating and preventing viral infection
WO2021190980A1 (en) 2020-03-22 2021-09-30 Quadrucept Bio Limited Multimers for viral strain evolution
EP3884957A1 (en) 2020-03-26 2021-09-29 The University of British Columbia Methods for treatment of virus and methods for screening of anti-virus reagent using organoids
US20230174611A1 (en) * 2020-04-24 2023-06-08 Administrators Of The Tulane Educational Fund Compositions and methods for preventing or reducing the effects of infections by coronaviruses that bind the extracellular domain of the ace2 receptor
CN113667016A (zh) * 2020-05-15 2021-11-19 普米斯生物技术(珠海)有限公司 一种构建冠状病毒抗体的平台
WO2021247675A1 (en) 2020-06-02 2021-12-09 Ngm Biopharmaceuticals, Inc. Coronavirus-binding agents and uses thereof
DE102020207224A1 (de) 2020-06-09 2021-12-09 Christoph Karle Protein oder Peptid, insbesondere zur Prophylaxe und/oder Behandlung einer durch Coronaviren, insbesondere SARS-CoV-2-Viren, hervorgerufenen Infektion oder Infektionskrankheit und/oder einer Folgekrankheit davon
WO2021263128A1 (en) * 2020-06-25 2021-12-30 Gliknik Inc. Ace2-fc fusion proteins and methods of use
WO2022008642A1 (en) 2020-07-08 2022-01-13 Apeiron Biologics Ag Treatment of sars-cov-2 infection with a combination of targets
WO2022011358A1 (en) * 2020-07-10 2022-01-13 Biomolecular Holdings Llc Tetrahedral antibodies
WO2022037699A1 (en) * 2020-08-21 2022-02-24 Westlake University Engineered ace2 oligomers and uses thereof
CN112280764A (zh) * 2020-11-18 2021-01-29 通用生物系统（安徽）有限公司 一种新冠重组ace2蛋白在哺乳动物细胞中的生产方法
EP4011387A1 (en) 2020-12-11 2022-06-15 IMBA-Institut für Molekulare Biotechnologie GmbH Superior neutralization of sars-cov-2 by deglycosylated human angiotensin converting enzyme 2
WO2022159433A1 (en) 2021-01-20 2022-07-28 Singh Biotechnology, Llc Therapeutics directed against coronavirus
WO2022184659A1 (en) 2021-03-01 2022-09-09 Quadrucept Bio Limited Antibody domains & multimers
WO2022207918A1 (en) 2021-04-02 2022-10-06 Apeiron Biologics Ag COVID-19 Therapy
WO2023023424A1 (en) * 2021-08-19 2023-02-23 Phenom Pharmaceuticals, Inc. Compositions and methods for treatment of sars cov-2
CN113897346A (zh) * 2021-09-16 2022-01-07 四川大学 能够提高与SARS-CoV-2 S蛋白亲和力的ACE2突变组合及应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6989363B1 (en) * 1997-12-11 2006-01-24 Millennium Pharmaceuticals, Inc. Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therefor
US6610497B1 (en) 1997-12-11 2003-08-26 Millennium Pharmaceuticals, Inc. Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therefor
US6194556B1 (en) * 1997-12-11 2001-02-27 Millennium Pharmaceuticals, Inc. Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therfor
SI2332582T1 (sl) * 2002-06-19 2014-03-31 Apeiron Biologics Ag Aktivacija ACE2 za zdravljenje srčne, pljučne in ledvične bolezni in hipertenzije
AU2003276877A1 (en) 2002-09-09 2004-03-29 Millenium Pharmaceuticals, Inc. Crystal structure of angiotensin-converting enzyme-related carboxypeptidase
EP1723962A1 (en) * 2005-05-19 2006-11-22 IMBA-Institut für Molekulare Biotechnologie GmbH Use of inhibitors of the renin-angiotensin system for the treatment of lung injuries
AT504443B1 (de) 2006-10-19 2008-11-15 Apeiron Biolog Forschungs Und Verfahren zur bestimmung der aktivität von ace2
EP2108695A1 (de) 2008-04-08 2009-10-14 Apeiron Biologics Forschungs- und Entwicklungsgesellschaft M.B.H. Ace2 Polypeptid
AT505262A1 (de) * 2007-06-12 2008-12-15 Apeiron Biolog Forschungs Und Rekombinantes ace2 polypeptid
AT506258A1 (de) * 2007-12-18 2009-07-15 Apeiron Biolog Forschungs Und Behandlung inflammatorischer krankheiten
AT506632A1 (de) * 2008-04-09 2009-10-15 Apeiron Biolog Forschungs Und Behandlung von tumorerkrankungen

Also Published As

Publication number Publication date
CY1120426T1 (el) 2019-07-10
US20180289779A1 (en) 2018-10-11
WO2008151347A1 (de) 2008-12-18
AU2008261591B2 (en) 2014-08-07
UA106869C2 (uk) 2014-10-27
HRP20180856T1 (hr) 2018-08-24
US20100310546A1 (en) 2010-12-09
JP2011519264A (ja) 2011-07-07
DK2155871T3 (en) 2015-11-09
PT2543724T (pt) 2018-06-11
US20140099297A1 (en) 2014-04-10
EP2543724B1 (de) 2018-03-21
EP2155871A1 (de) 2010-02-24
IL202653B (en) 2018-01-31
CY1116873T1 (el) 2017-04-05
IL202653A0 (en) 2011-08-01
HUE037877T2 (hu) 2018-09-28
EA201000002A1 (ru) 2010-08-30
KR20160054045A (ko) 2016-05-13
DOP2009000282A (es) 2010-03-31
EG27095A (en) 2015-05-28
EA027399B1 (ru) 2017-07-31
ES2550390T3 (es) 2015-11-06
CO6270265A2 (es) 2011-04-20
BRPI0813942B1 (pt) 2019-08-20
MY180672A (en) 2020-12-05
AU2008261591A1 (en) 2008-12-18
EP3375872A1 (de) 2018-09-19
PT2155871E (pt) 2015-10-26
AT505262A1 (de) 2008-12-15
JP5731193B2 (ja) 2015-06-10
ES2670938T3 (es) 2018-06-04
BRPI0813942B8 (pt) 2021-05-25
PL2543724T3 (pl) 2018-08-31
US8586319B2 (en) 2013-11-19
TR201808117T4 (tr) 2018-07-23
US10716833B2 (en) 2020-07-21
EP2543724A3 (de) 2013-02-20
EP2543724A2 (de) 2013-01-09
CA2692854A1 (en) 2008-12-18
NZ581704A (en) 2012-05-25
RS54340B1 (en) 2016-02-29
BRPI0813942A2 (pt) 2014-12-30
DK2543724T3 (en) 2018-05-28
EP2155871B1 (de) 2015-08-12
HK1255493A1 (zh) 2019-08-16
HK1136602A1 (en) 2010-07-02
ZA200908751B (en) 2010-07-28
CN104450654A (zh) 2015-03-25
HUE028012T2 (en) 2016-11-28
NO2543724T3 (es) 2018-08-18
KR101682240B1 (ko) 2016-12-06
SI2155871T1 (sl) 2015-11-30
PL2155871T3 (pl) 2015-12-31
KR20100040809A (ko) 2010-04-21
HRP20151120T1 (en) 2015-11-20
LT2543724T (lt) 2018-06-25
MA31472B1 (fr) 2010-06-01
RS57292B1 (sr) 2018-08-31
CN101796183A (zh) 2010-08-04
SI2543724T1 (en) 2018-07-31
CR11213A (es) 2010-04-20
CA2692854C (en) 2017-07-04

Similar Documents

Publication Publication Date Title
MX2009013472A (es) Polipeptido ace2.
AU2017204797B2 (en) Antibodies with modified isoelectric points
MX2013015393A (es) Inmunocitosinas basadas en un dominio sushi de il-15 y de il-15ra.
EP4269441A3 (en) Il-15 and il-15ralpha sushi domain based on modulokines
WO2008145137A3 (en) Recombinant non glycosylated monovalent half-antibodies obtained by molecular engineering
PL2032713T3 (pl) Sposoby wytwarzania hydrolizatu skrobi
EP1981979A4 (en) PROCESS FOR PRODUCING A SOLUBLE NATIVE FORM OF RECOMBINANT PROTEIN USING THE SIGNAL SEQUENCE AND A SECRETION ENHANCING AGENT
PL1999160T3 (pl) Akrylowany kwas hialuronowy
EP2032261A4 (en) FIBER MATERIALS AND COMPOSITIONS
WO2013052946A3 (en) Genetically encoded biosensors
EA201171325A1 (ru) Нуклеиновые кислоты, связывающиеся с гепсидином
WO2010034718A8 (fr) Proteines recombinantes a activite hemostatique capables d'induire l'agregation plaquettaire
MY144455A (en) Novel viral vector
EP2057002A4 (en) MOLDING AND MIXING SYSTEM, AMONG OTHER THINGS
MX2012004847A (es) Proucto proteico estructurado libre de gluten.
BR112012007990A2 (pt) preparado farmacêutico compreendendo hcg recombinante
MX2011012623A (es) Construcciones de casb7439.
PL2296487T3 (pl) Sposób wytwarzania hydrolizatu białka pszenicy
GB201012090D0 (en) Cellulosic material
WO2009131698A3 (en) PHOSPHORYLATED RECOMBINANT N-ACETYL-alpha-D- GLUCOSAMINIDASE (NaGlu) AND USES THEREOF
WO2010108182A3 (en) Production of recombinant proteins in ciliates and uses thereof
MX2009013921A (es) Material refractario sin forma, un proceso para producir un material refractario sin forma, humedo como la tierra, y al uso del material refractario sin forma.
EP2569327A4 (en) EIF4E BINDING PEPTIDES
MX2010009960A (es) Producto ceramico refractario y un moldeado asociado.
IN2012DN01557A (es)

Legal Events

Date Code Title Description
FG Grant or registration